MEFV mutations - therapeutic guides or red herrings? by unknown
POSTER PRESENTATION Open Access
MEFV mutations - therapeutic guides or red
herrings?
K Warrier1*, L Cliffe2, L McDermott1,3, S Rangaraj1
From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015
Background/question
Familial Mediterranean Fever (FMF) is a hereditary
inflammatory disorder characterised by self-resolving
attacks of fever and serositis common in populations
from Mediterranean ancestry [1]. Mutations affecting
MEFV gene is believed to be responsible for the disease
phenotype[1]. The correlation between the genotype and
phenotype is not very strong, indicating the presence of
other modifying factors which alter clinical manifesta-
tion. We describe 2 children with autoinflammtory
symptoms, who had MEFV mutations, the significance
of which we are unsure of.
Methods
A 13-year-old Polish girl of Romani descent of non-con-
sanguineous parents presented with one-week history of
fever, chest pain and vomiting. She was alert; but pale,
tachycardic and hypotensive with normal capillary filling
time and warm peripheries, despite saline boluses and
broad spectrum antibiotics. She had no rash, mouth
ulcers, lymphadenopathy or hepatosplenomegaly. Her
investigations showed leucocytosis (22.2 × 109/L) with
neutrophilia (20.2), hypoalbuminaemia (19g/L) and high
inflammatory markers (CRP 222mg/L/ ESR 142mm/
hour). She had past history of 3 -4 similar episodes
every year since 5 years of age, one of which needed a
lengthy admission to the Intensive Care Unit. She was
then advised a 3-day course of oral Prednisolone at the
onset of each episode, to which she did not respond this
time. She continued to spike temperature in excess of
39°C daily for the next five weeks. Her inflammatory
markers went up further, along with high ferritin (3729
microg/L) and LDH (1003 U/L) with persistent hypoal-
buminaemia, leucocytosis with neutrophilia and
thrombocytosis (platelets 597 × 109/L) and worsening
anaemia (Haemoglobin 63 g/L). Investigations for an
underlying immunodeficiency, infection, autoimmune
disorder, macrophage activation and inflammatory bowel
disease were negative. Her serum Amyloid A (SAA) was
798 mg/L. A diagnosis of an unclassified autoinflammatory
disorder was made by exclusion, for which she was com-
menced on Anakinra at 100mg daily. Her symptoms settled
and investigations normalised dramatically, including SAA.
Her autoinflammtory genetics screen later revealed she is
positive for MEFV E148Q mutation. Because her symptoms
were not typical of FMF and were well controlled on
Anakinra, treatment was not altered.
A 2-year-old boy of non-consanguineous parents of
Indian origin was referred with recurrent episodes of
high fevers lasting 4 days, since nine months of age with
frequency increasing from 8 weeks to every 3 weeks. A
typical episode starts with him rubbing ears and nose,
followed by fever up to 40°c, with little response to Para-
cetamol and Ibuprofen. He had no other symptoms dur-
ing or between these episodes. Two maternal nieces had
recurrent fevers when young, which improved with ton-
sillectomy. His examination was normal with no rashes,
mouth ulcers, lymphadenopathy or hepatosplenomegaly,
although he had large tonsils with small cervical lymph
nodes. He had raised inflammatory markers during the
episodes. With a possible diagnosis of PFAPA syndrome,
he was advised a single dose of Prednisolone at 2mg per
kg at the start of an attack. He responded to Prednisolone
during subsequent attacks, but parents were concerned
about worsening frequency. His autoinflammtory genet-
ics screen revealed a mutation in E148Q in exon 2 of the
MEFV gene. His clinical features were not typical of FMF
without any evidence of serositis and good response to
Prednisolone, which prompted us to withhold Colchicine
for the time being.1Nottingham University Hospitals NHS Trust, Paediatric Rheumatology,
Nottingham, UK
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Results and conclusion
Although E148Q is one of the one of the five most fre-
quent MEFV mutations in the classically affected ethnic
groups, it is considered to be the mildest and least pene-
trant with no reported incidence of amyloidosis [1].
Some studies [3] report a high frequency of E148Q
mutation (21%) in Indian population used as control, an
ancestry both these patients may well share. Although it
may cause FMF when associated with certain other
MEFV mutations, homozygosity for E148Q alone must
be insufficient to produce FMF [3]. That leaves us with
the question of the significance of the mutations in
these children, who do not have classical symptoms of
FMF but are significantly symptomatic, especially with
regards to switching therapy when there is a response to
the existing agent.
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